Recombinant human arylsulfatase A

Protein / enzyme

Recombinant human arylsulfatase A is one of 6 biologic programs targeting Metachromatic Leukodystrophy. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metachromatic LeukodystrophyActive, not recruiting

Metachromatic LeukodystrophyPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Metachromatic Leukodystrophy

#DrugCompanyPhaseTrials

Busulfex

Akero Therapeutics

Approved

—2

Cytoxan

BBaxter Healthcare Corporation

RG6026

SHP611

Coumadin

1 6

Recombinant human arylsulfatase A

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metachromatic Leukodystrophy2 trials

Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)

Completed· Takeda logo

Takeda·Phase 1/2·NCT00633139·13 enrolled

Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)

Completed· Takeda logo

Takeda·Phase 1/2·NCT01510028·24 enrolled

MPS IIIA1 trial

Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients

Completed· Takeda logo

Takeda·Phase 1/2·NCT01155778·12 enrolled

Adult Subject1 trial

Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

Completed· Takeda logo

Takeda·Phase 1·NCT02663687·48 enrolled

Safety and Efficacy1 trial

Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease

Completed· Takeda logo

Takeda·Phase 2·NCT02060526·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Recombinant human arylsulfatase A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant human arylsulfatase A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant human arylsulfatase A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Company: Takeda

Recombinant human arylsulfatase A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metachromatic Leukodystrophy2 trials

MPS IIIA1 trial

Adult Subject1 trial

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News